Investor Backing & Capital Strength:
Recent financing includes an $80M Series C in April 2026, bringing total funding above $160M and implying a valuation near $955M. Feedback suggests this capital is earmarked to expand AI capabilities and go‑to‑market, reinforcing runway and scale.
Strong Market Position & Advantage:
The company reports supporting 16 of the top 20 MedTech companies and crossing the 300‑customer mark by 2025, indicating deep enterprise penetration. Hundreds of MedTech organizations and large identified pipeline point to solid positioning within its niche.
Innovation-Driven Growth:
Ongoing platform expansion includes AI features launched in 2025 and expanded “agentic AI” tied to the 2026 raise. This cadence indicates active investment in R&D and commercial enablement.
